Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has dosed the first patient in the Company’s Phase 1/2 clinical trial evaluating the safety and efficacy of an investigational AAV-based gene therapy for the treatment of X-linked retinitis pigmentosa (XLRP). Read More »

Merck known as MSD outside the United States and Canada, and Invenergy, North America’s largest privately held renewable energy company, announced a Virtual Power Purchase Agreement (VPPA) that adds 60 megawatts (MW) of renewable energy to the electrical grid and supports Merck’s environmental sustainability goals. Read More »

Mylan Presents Equivalence Data on Glatiramer Acetate Compared to Copaxone® at American Academy of Neurology 70th Annual Meeting Read More »

Mallinckrodt Pharmaceuticals , a leading global specialty pharmaceutical company, will present on Tuesday, May 22, 2018, at the UBS Global Healthcare Conference at the Grand Hyatt New York, 109 East 42nd St., New York. Read More »

The Board of Directors of McKesson today released its response to a request from the International Brotherhood of Teamsters, a McKesson stockholder, that the Board perform an investigation into senior management’s and the Board’s oversight of McKesson’s compliance with its legal and regulatory obligations relating to the distribution of opioids. Read More »

Mallinckrodt plc a leading global specialty pharmaceutical company, announced the $300 million repayment of unsecured, fixed-rate notes maturing April 15, 2018 with cash on hand. Read More »

Amgen announced that it will report its first quarter 2018 financial results on Tuesday, April 24, 2018, after the close of the U.S. financial markets. Read More »

Aetna’s recently announced expansion efforts in Wellesley, Mass., not only demonstrate the company’s commitment to the local community, but to transforming the consumer health experience. Read More »

Amarin Corporation plc a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular (CV) health, announced that Aaron Berg has been promoted to the position of Senior Vice President, Chief Commercial Officer. Read More »

The nominating committees for the ASHP Pharmacy Practice Sections recently approved candidates for Executive Committee Chairs and Directors-at-Large. Read More »

The ASHP Committee on Nominations met on April 19 and approved the following ASHP members as candidates for ASHP elected offices: Read More »

The leading global biotechnology company focused on rare diseases, announced that the Swiss Agency for Therapeutic Products (Swissmedic) has validated the marketing authorization application (MAA) for lanadelumab (SHP643). Read More »

The American Hospital Association (AHA), ASHP, and the Federation of American Hospitals (FAH) are fielding a survey to all community hospitals and health systems to collect quantitative, representative data on pharmaceutical drug spending and the impact of drug shortages. Read More »

The leading global biotechnology company focused on rare diseases announces today that it has entered into a definitive agreement with Servier S.A.S. (“Servier”) to sell its Oncology business for $2.4 billion. Read More »

Online Training Education Program Readies Pharmacists, Technicians to Prepare Sterile Products Read More »

Just announced that the company is beginning two Phase 3 studies of PCV-15 (V114), its investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease. Read More »

Tagrisso delivered unprecedented median progression-free survival of 18.9 months versus 10.2 months compared with current standard of care Read More »

The global biotechnology leader in rare disease, just announced the U.S. Food and Drug Administration (FDA) has approved VONVENDI [von Willebrand factor (recombinant)], a recombinant von Willebrand factor (rVWF) treatment for perioperative management of bleeding in adults (age 18 and older) with von Willebrand disease (VWD).1 VONVENDI is also indicated for on-demand treatment and control of bleeding episodes, and it is the first and only recombinant treatment for adults living with VWD, the most common inherited bleeding disorder.1,3-4 Read More »

New Guidelines Call for Standardized Approach to Managing Investigational Drug Products Read More »

The man looked to be in his mid to late 30s and, at a glance, not someone who a stranger would suspect of having a substance use disorder, said Michelle Maguire, emergency medicine pharmacy resident at Massachusetts General Hospital in Boston. Read More »